The test runs on the company's OneBreath platform and is designed to assess a patient's risk for postoperative pneumonia.
The cleared assays included point-of-care and home tests for infectious and chronic diseases and drugs of abuse.
The tests were developed by France's NG Biotech, which exclusively licensed their US distribution rights to Hardy.
The company reported revenue of $3.52 billion, up from $3.33 billion in Q4 2024 but below the Wall Street consensus estimate of $3.56 billion.
Net proceeds from the private placement will be used to fund ongoing operations, address outstanding liabilities, and preserve the company's ability to operate.
The automated image assessment software uses artificial intelligence to sort images of bacterial culture plates.
The agreement pertains to multiple immunoassay analyzers and test menus that QuidelOrtho expects will increase its competitiveness in international tenders.
NEW YORK — Bio-Techne said on Monday that its Ella benchtop immunoassay platform has received CE-IVD marking, permitting its sale in the EU.
NEW YORK – Lex Diagnostics said on Monday that it has obtained 510 (k) clearance and CLIA waiver from the US Food and Drug Administration for its Velo point-of-care molecular diagnostic system and an ...
Last week, readers were most interested in a story about the use of blood-based tests for asymptomatic Alzheimer's patients.
The firm saw a 26 percent increase in screening revenue and a 14 percent increase in precision oncology revenue during the quarter.
The transition from testing the dead to testing the living is the latest example of how genomics is expanding horizons for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results